Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Recommendation of "Buy" by Analysts

Shares of Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) have been given an average recommendation of "Buy" by the five brokerages that are currently covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $78.50.

PCVX has been the topic of several analyst reports. Bank of America raised their target price on Vaxcyte from $67.00 to $80.00 and gave the company a "buy" rating in a report on Tuesday, January 2nd. Mizuho started coverage on Vaxcyte in a report on Thursday, December 7th. They set a "buy" rating and a $69.00 target price on the stock. Needham & Company LLC lifted their price objective on Vaxcyte from $73.00 to $95.00 and gave the stock a "buy" rating in a report on Wednesday, February 28th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Vaxcyte in a research report on Friday, January 12th.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the company's stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $60.73, for a total value of $485,840.00. Following the transaction, the chief financial officer now directly owns 79,474 shares of the company's stock, valued at approximately $4,826,456.02. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CFO Andrew Guggenhime sold 8,000 shares of the business's stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $60.73, for a total value of $485,840.00. Following the completion of the sale, the chief financial officer now directly owns 79,474 shares in the company, valued at approximately $4,826,456.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Mikhail Eydelman sold 1,667 shares of the business's stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $63.93, for a total value of $106,571.31. Following the completion of the sale, the senior vice president now owns 20,710 shares of the company's stock, valued at $1,323,990.30. The disclosure for this sale can be found here. Insiders have sold a total of 129,860 shares of company stock valued at $8,720,633 in the last three months. Corporate insiders own 3.60% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP grew its stake in Vaxcyte by 3.8% during the 3rd quarter. Wellington Management Group LLP now owns 4,598,712 shares of the company's stock worth $234,442,000 after buying an additional 167,501 shares during the last quarter. Jennison Associates LLC grew its stake in Vaxcyte by 20.6% during the 3rd quarter. Jennison Associates LLC now owns 1,754,691 shares of the company's stock worth $89,454,000 after buying an additional 300,189 shares during the last quarter. UBS Group AG grew its stake in Vaxcyte by 62.2% during the 3rd quarter. UBS Group AG now owns 74,305 shares of the company's stock worth $3,788,000 after buying an additional 28,483 shares during the last quarter. Vanguard Group Inc. grew its stake in Vaxcyte by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 8,284,246 shares of the company's stock worth $422,331,000 after buying an additional 47,872 shares during the last quarter. Finally, Barclays PLC grew its stake in Vaxcyte by 67.9% during the 3rd quarter. Barclays PLC now owns 170,412 shares of the company's stock worth $8,688,000 after buying an additional 68,904 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Trading Down 0.3 %

Shares of Vaxcyte stock traded down $0.19 during trading hours on Friday, reaching $68.31. The stock had a trading volume of 731,552 shares, compared to its average volume of 669,441. The firm has a market capitalization of $7.41 billion, a price-to-earnings ratio of -16.54 and a beta of 0.91. Vaxcyte has a 1 year low of $34.11 and a 1 year high of $82.04. The firm has a 50 day simple moving average of $71.21 and a two-hundred day simple moving average of $59.55.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Tuesday, February 27th. The company reported ($1.82) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.93). During the same quarter last year, the firm posted ($0.73) earnings per share. Sell-side analysts forecast that Vaxcyte will post -4.18 EPS for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.